Immuno-oncology company Agenus Inc (NASDAQ: AGEN) reported on Wednesday the start of its Phase I clinical trial of an undisclosed antibody candidate.
The company's Phase I clinical trial was initiated by its partner, Merk.
Under the terms of the agreement, Agenus received a USD4m milestone payment and is entitled to receive up to an additional USD95m in success milestones from Merck.
This milestone is reportedly the second under the collaboration originally announced in April 2014.
Pursuant to the agreement, Merck is responsible for all product development expenses for the antibody candidate, and Agenus is eligible to receive up to an additional USD95m in milestone payments, as well as royalties on worldwide product sales.
Foresee gains NMPA approval for CAMCEVI 42 mg in China
ABL Texcell Diagnostics acquires IntegraGen assets to expand into precision oncology
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
Alpheus Medical starts new clinical trial of PoMA therapy in butterfly glioblastoma
Sophos IRB and ALCMI partner to support lung cancer research
Northwest Biotherapeutics and NHSBT collaborate to support production of DCVax-L
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
Voyager signs cancer research mission management contract
AstraZeneca completes USD2bn equity investment in Summit Therapeutics
GE HealthCare to acquire SOFIE Biosciences for USD945m
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK